Quadrivalent HPV 6/11/16/18 vaccine;Quadrivalent vaccine mod humant papillomvirus til forebyggelse af svære celleforandringer på livmoderhalsen - Sekundæ rpublikation

Ugeskrift for Laeger

Volumn 169, Issue 46, 2007, Pages 3971-3974

  Kjær, Sussane Krüger ^a   Andersen, Erik Søgård ^b   Djursing, Henning ^b   Hansen, Tom ^b   Jørgensen, Jens Jørgen ^b   Nilas, Lisbeth ^b   Ottesen, Bent S ^b   Petersen, Lone Keld ^b   Thomsen, Steen Grove ^b   Toftager Larsen, Kim ^b  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38749095911     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. Lyon, France: IARC Press. www-dep.iart.friglobocan/methods.htm /apr 2007.
2. Muñoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Preventive human papillomavirus (HPV) vaccines - regulatory briefing document on endpoints. V. Presented at the Vaccines and Related Biological Products Advisory Committee Meeting. Bethesda, MD, November 28-29, 2001. www.fda.gov./ohrms/dockets/ac/01/briefing/3805b1_01.htm /apr 2007.
4. Wiley DJ, Douglas J, Beutner K et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35(suppl 2):S210-S224.
5. Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27. Erratum. Obstet Gynecol 2006;107:1425.
6. Villa LL, Costa RLR, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
7. Harper DM, Franco E, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized controlled trial. Lancet 2006;367:1247-55.
8. Olsson SE, Villa LL, Costa RLR et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine. Vaccine 2007;25:4931-9.
9. Lehtinen M, Herrero R, Mayaud P et al. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006;24(suppl 3):S233-S241.